Josh SullivanAssociate Editor AbbVie’s age-related blurry vision drug for aging adults was given the OK by the FDA Friday, making it the first eye drop to treat an eye condition that affects 128 million Americans. Formerly AGN-190584, the drug has proven a bright spot in Allergan’s pipeline since AbbVie bought it out for $63 billion,...